Otonomy Reports Second Quarter 2021 Financial Results and Provides Corporate Update
04 août 2021 16h16 HE
|
Otonomy, Inc.
OTO-313 Phase 2 trial in tinnitus ongoing with results expected in mid-2022OTO-413 Phase 1/2 trial expansion in hearing loss ongoing with results expected in mid-2022OTO-825 preclinical...
Otonomy to Report Second Quarter 2021 Financial Results and Provide Corporate Update
28 juil. 2021 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy Initiates Expansion of Phase 1/2 Clinical Trial for OTO-413 in Hearing Loss
15 juin 2021 07h30 HE
|
Otonomy, Inc.
OTO-413 demonstrated a higher proportion of responders than placebo based on multiple speech-in-noise hearing tests in dose escalation efficacy cohortExpansion study will support endpoint selection...
Otonomy and AGTC Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting
14 mai 2021 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, May 14, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced...
Otonomy Reports First Quarter 2021 Financial Results and Provides Corporate Update
11 mai 2021 16h17 HE
|
Otonomy, Inc.
OTO-313 Phase 2 trial in tinnitus initiated with results expected in mid-2022OTO-413 Phase 1/2 trial expansion in hearing loss expected to start in second quarter of 2021 with results anticipated in...
Otonomy to Report First Quarter 2021 Financial Results and Provide Corporate Update
04 mai 2021 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will...
Otonomy and AGTC to Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting
28 avr. 2021 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, April 28, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
19 avr. 2021 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, April 19, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy Announces Pricing of $30.1 Million Public Offering
07 avr. 2021 22h02 HE
|
Otonomy, Inc.
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy Announces Proposed Public Offering
07 avr. 2021 16h06 HE
|
Otonomy, Inc.
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...